These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38718845)

  • 1. Obeticholic acid attenuates the intestinal barrier disruption in a rat model of short bowel syndrome.
    Hou L; Wang H; Yan M; Cai Y; Zheng R; Ma Y; Tang W; Jiang W
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167221. PubMed ID: 38718845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
    Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
    Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Mediators From Lactobacillus rhamnosus Gorbach-Goldin Support Intestinal Barrier Function in Rats After Massive Small-Bowel Resection.
    Wu J; Yang K; Wu W; Tang Q; Zhong Y; Gross G; Lambers TT; van Tol EAF; Cai W
    JPEN J Parenter Enteral Nutr; 2018 Aug; 42(6):1026-1034. PubMed ID: 30133842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.
    Ceulemans LJ; Verbeke L; Decuypere JP; Farré R; De Hertogh G; Lenaerts K; Jochmans I; Monbaliu D; Nevens F; Tack J; Laleman W; Pirenne J
    PLoS One; 2017; 12(1):e0169331. PubMed ID: 28060943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction.
    Yan M; Hou L; Cai Y; Wang H; Ma Y; Geng Q; Jiang W; Tang W
    Front Pharmacol; 2022; 13():906452. PubMed ID: 35770078
    [No Abstract]   [Full Text] [Related]  

  • 7. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
    Friedman ES; Li Y; Shen TD; Jiang J; Chau L; Adorini L; Babakhani F; Edwards J; Shapiro D; Zhao C; Carr RM; Bittinger K; Li H; Wu GD
    Gastroenterology; 2018 Dec; 155(6):1741-1752.e5. PubMed ID: 30144429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
    Villalona G; Price A; Blomenkamp K; Manithody C; Saxena S; Ratchford T; Westrich M; Kakarla V; Pochampally S; Phillips W; Heafner N; Korremla N; Greenspon J; Guzman MA; Kumar Jain A
    JPEN J Parenter Enteral Nutr; 2018 Nov; 42(8):1238-1251. PubMed ID: 29701901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral insulin stimulates intestinal epithelial cell turnover following massive small bowel resection in a rat and a cell culture model.
    Ben Lulu S; Coran AG; Shehadeh N; Shamir R; Mogilner JG; Sukhotnik I
    Pediatr Surg Int; 2012 Feb; 28(2):179-87. PubMed ID: 21986618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired intestinal FXR signaling is involved in aberrant stem cell function leading to intestinal failure-associated liver disease in pediatric patients with short bowel syndrome.
    Zhao Y; Wang Y; Jiang L; Cai W; Yan J
    FASEB J; 2024 Aug; 38(15):e23847. PubMed ID: 39096137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
    Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteral supplementation of bovine lactoferrin improves gut barrier function in rats after massive bowel resection.
    Wu J; Chen J; Wu W; Shi J; Zhong Y; van Tol EA; Tang Q; Cai W
    Br J Nutr; 2014 Aug; 112(4):486-92. PubMed ID: 24830343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
    Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
    Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.
    Lu D; Liu Y; Luo Y; Zhao J; Feng C; Xue L; Xu J; Wang Q; Yan T; Xiao P; Krausz KW; Gonzalez FJ; Xie C
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Feb; 1867(2):159089. PubMed ID: 34856412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
    Pereira-Fantini PM; Lapthorne S; Joyce SA; Dellios NL; Wilson G; Fouhy F; Thomas SL; Scurr M; Hill C; Gahan CG; Cotter PD; Fuller PJ; Hardikar W; Bines JE
    J Hepatol; 2014 Nov; 61(5):1115-25. PubMed ID: 24999016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
    Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
    Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.